Sign In
NewsRadar

Search Press
Looking for press releases of a particular company? Enter company name (or keyword) here.

   


Gastrotech completes $6 million Series D fundraising
Funds earmarked for Phase II development of two lead products


Copenhagen, 11 February 2008 … Gastrotech Pharma, a clinical stage biopharmaceutical company with a focus on the medical applications of gastrointestinal hormones, has successfully completed a $6 million Series D fundraising round. The lead investor was CAT Invest I A/S (Copenhagen, Denmark), and other investors included Nordic Biotech, BML Healthcare I LP, and 123MultiNova Europe, all existing investors in the company.

The funding will be used to support the Phase IIb clinical development programme on GTP-010, the company’s lead programme for the treatment of pain in irritable bowel disease. In addition it will also be used to advance the Phase II development of GTP-300, a ghrelin peptide, for treatment of cancer-associated cachexia and anorexia. Ghrelin is a naturally occurring hormone, which stimulates the appetite. By increasing levels of ghrelin, Gastrotech believes it will be possible to stop the problems of catabolic syndrome (anorexia and cachexia) associated with cancer.

Enda Kenny, Gastrotech Pharma CEO, said: “This funding is excellent news for Gastrotech, and will allow us to develop our clinical programmes further. This, coupled with the in-licensing of GTP-010 from Eli Lilly and Company, means Gastrotech is now in a very good position, with funding secured and a number of exciting compounds in development.”

Leif Helth Jensen, Investment Manager of CAT Invest I said: “Gastrotech Pharma is a very attractive investment opportunity for us. It has two products in clinical development which address unmet clinical needs and both are in substantial market areas. As a Danish Biotech company, it also fits our strategic focus.”

Hans Schambye, Chairman of Gastrotech Pharma said: “These achievements now allow us to fully exploit our unique approaches to the management of pain in IBS and anorexia in cancer which are both major unmet clinical needs.”


-ENDS-

About Gastrotech Pharma

Gastrotech Pharma A/S (www.gastrotechpharma.com) is a clinical stage biotechnology company focused on the development of novel treatments for IBS and anorexia/cachexia associated with cancer and other major pathologies.

About CAT Invest I and CAT Science Park A/S

The CAT Invest I fund is operated and managed by CAT Science Park A/S (www.catscience.dk), a privately-held company, helping entrepreneurs and innovators to find the capital and the right competences required to turn ideas into enterprises. CAT Science Park is a unique combination of government-backed, pre-seed capital, science park, and venture company. The company functions both as host as well as mentor for good ideas. All the way – from the first tentative steps to a viable enterprise.

About GTP-010

GTP-010 is an analogue of GLP-1, a naturally occurring intestinal hormone that plays an important physiological role in assisting the human body to maintain appropriate blood sugar levels and modulate gastric motility following meals. GTP-010 has a longer half life than the natural hormone, and is maintained in the circulation during the acute phase of an IBS pain attack. Here it modulates contractile activity and delays gastric emptying before it is cleared by natural mechanisms.

About Irritable Bowel Syndrome

Irritable Bowel Syndrome (IBS) is a very common disorder with approximately 75 million sufferers in the developed world. Between 10-20% of the general population exhibit symptoms characterized by bloating, abnormal motility patterns, visceral hypersensitivity, discomfort and pain which can be severe. Current treatments are symptomatic with antispasmodics and low dose tricyclic antidepressants prescribed for frequent or severe pain. The treatment of pain is a significant unmet need in IBS.

About Cancer-associated cachexia and anorexia

Cachexia is a leading cause of cancer related mortality, affecting 50% of all cancer patients. It occurs in virtually all cancer types and accounts for 30% of cancer related deaths with some 900,


Publisher Contact Information:

Gastrotech Pharma A/S
+45 39179745
ek@gastrotechpharma.com

Company profile of Gastrotech Pharma A/S
Past press releases of Gastrotech Pharma A/S.

Data


25,099
Tech investments
From our Online Data Service
16,240
VC-backed companies
From our Radar


Recent Deals


DATEAMOUNTSECTOR
Dec 7€6.3MNanotechnology
Dec 7€21.1MInternet commerce
Dec 7€4.8MInternet commerce
Dec 7€1.8MInternet commerce
Dec 6N/AInternet commerce
Dec 6€26.0MBusiness applications
Dec 6€5.6MMedical devices

For information on Europe's most extensive database on technology funding click here!

Events



Press Releases


Oct 1
The Link App
the link app launches version 2.0

Mar 29
Addex Therapeutics
addex sucessfully raises chf40 million in capital increase

Jan 2
Urban Jungle
urban jungle raises £1m in seed funding to build tech-enabled home ...

Aug 17
Komed Health
komed health closes seed financing round

Jul 10
Komed Health
komed health to be supported by nokia and deutsche telekom





About usContact usLegal Information
Copyright © 1999-2018
Emerging Technology Research Europe Inc. All rights reserved.